Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).